Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.
Ontology highlight
ABSTRACT: Hodgkin lymphoma (HL) is a lymphoid malignancy that is typically derived from germinal-center B cells. EBV infection, mutations in NF-κB pathway genes, and genetic susceptibility are known risk factors for developing HL. CD30 and NF-κB have been identified as potential biomarkers in pediatric HL patients, and these molecules may represent therapeutic targets. Although current risk adapted and response based treatment approaches yield overall survival rates of >95%, treatment of relapse or refractory patients remains challenging. Targeted HL therapy with the antibody-drug conjugate Brentuximab vedotin (Bv) has proven to be superior to conventional salvage chemotherapy and clinical trials are being conducted to incorporate Bv into frontline therapy that substitutes Bv for alkylating agents t
SUBMITTER: Nagpal P
PROVIDER: S-EPMC5341896 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA